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Background
Limited clinical and laboratory data are available on patients with Ebola virus disease 
(EVD). The Kenema Government Hospital in Sierra Leone, which had an existing in-
frastructure for research regarding viral hemorrhagic fever, has received and cared for 
patients with EVD since the beginning of the outbreak in Sierra Leone in May 2014.
Methods
We reviewed available epidemiologic, clinical, and laboratory records of patients in 
whom EVD was diagnosed between May 25 and June 18, 2014. We used quantitative 
reverse-transcriptase–polymerase-chain-reaction assays to assess the load of Ebola 
virus (EBOV, Zaire species) in a subgroup of patients.
Results
Of 106 patients in whom EVD was diagnosed, 87 had a known outcome, and 44 had 
detailed clinical information available. The incubation period was estimated to be 
6 to 12 days, and the case fatality rate was 74%. Common findings at presentation 
included fever (in 89% of the patients), headache (in 80%), weakness (in 66%), dizzi-
ness (in 60%), diarrhea (in 51%), abdominal pain (in 40%), and vomiting (in 34%). 
Clinical and laboratory factors at presentation that were associated with a fatal 
outcome included fever, weakness, dizziness, diarrhea, and elevated levels of blood 
urea nitrogen, aspartate aminotransferase, and creatinine. Exploratory analyses 
indicated that patients under the age of 21 years had a lower case fatality rate than 
those over the age of 45 years (57% vs. 94%, P = 0.03), and patients presenting with 
fewer than 100,000 EBOV copies per milliliter had a lower case fatality rate than 
those with 10 million EBOV copies per milliliter or more (33% vs. 94%, P = 0.003). 
Bleeding occurred in only 1 patient.
Conclusions
The incubation period and case fatality rate among patients with EVD in Sierra Leone 
are similar to those observed elsewhere in the 2014 outbreak and in previous out-
breaks. Although bleeding was an infrequent finding, diarrhea and other gastrointes-
tinal manifestations were common. (Funded by the National Institutes of Health and 
others.)
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The largest and most widespread outbreak of Ebola virus disease (EVD) continues to spread through West Africa, 
with more than 10,100 cases reported in Guinea, 
Sierra Leone, Liberia, Senegal, Nigeria, and Mali 
as of October 25, 2014.1 The possibility of global 
spread of the disease was realized recently with 
the diagnosis of EVD in patients in the United 
States and Spain.2 The EVD outbreak appears to 
have originated near the town of Guéckédou, 
which is in the forest region of Guinea and close 
to the borders of Sierra Leone and Liberia.3,4 Se-
quence analyses indicated that the West African 
variant of Ebola virus (EBOV, Zaire species) di-
verged from Middle African lineages approxi-
mately a decade ago.5 Genetic similarity across 
the 2014 samples suggests a single introduction 
from an animal reservoir, with human-to-human 
transmission sustaining the outbreak.
EBOV infection presents many challenges to 
clinical management.6,7 Case fatality rates in past 
EVD outbreaks have ranged from 45 to 90%.8 
Exposure to EBOV-infected patients is a hazard 
for health care providers, one that has been ex-
acerbated by the scale of the current outbreak. 
There are currently no approved treatments for 
EVD, although supportive care, including the 
administration of intravenous fluids and empiri-
cal use of antibiotics, is thought to be important. 
Care in clinical settings that have advanced 
medical expertise available may increase survival 
by facilitating maintenance of hydration, circula-
tory volume, and blood pressure.7
In past outbreaks, EVD has been characterized 
by a constellation of signs and symptoms begin-
ning with fever and progressing to diarrhea, 
vomiting, and, in a subgroup of patients, hemor-
rhage.6,9,10 However, the sporadic nature of 
EBOV outbreaks and their occurrence in remote, 
resource-limited settings have precluded the 
acquisition of extensive clinical and laboratory 
data. The natural history of EVD in the current 
outbreak may vary from that in previous out-
breaks.
For the past decade, Kenema Government 
Hospital, located in the Eastern Province of Sierra 
Leone, has maintained a clinical research pro-
gram on Lassa hemorrhagic fever, a viral disease 
that is endemic in West Africa.11,12 Because of its 
proximity to the epicenter of the EBOV outbreak 
in Guinea, the Lassa Fever Team mobilized to 
establish EBOV surveillance and diagnostic capa-
bilities before entry of the virus into the country. 
Lassa team scientists confirmed the first cases 
of EVD in Sierra Leone on May 25, 2014.5 The 
existing infrastructure for clinical and labora-
tory research regarding viral hemorrhagic fever 
provided opportunities to evaluate EVD-associated 
disease. Here, we present the available data on 
the first 106 patients in whom EVD was diag-
nosed as the disease spread to Sierra Leone in 
order to provide a basis for understanding the 
clinical illness.
Me thods
Patients
Before the detection of EVD in Sierra Leone, pa-
tients were referred to Kenema Government Hos-
pital for testing and treatment if they had an ill-
ness that met the definition of a suspected Lassa 
case.11 After the initial cases of EVD were de-
tected, patients were referred if they presented 
with an illness that met the World Health Orga-
nization case definition for EVD.13
Data Collection
All clinical and laboratory data-collection forms 
were being used at Kenema Government Hospital 
for the treatment of patients with viral hemor-
rhagic fever before the EVD outbreak. In addi-
tion, a blood-sampling protocol was in place to 
obtain specimens, if deemed appropriate by the 
treating physician, from all patients admitted to 
the ward. Demographic, clinical, and treatment 
data were recorded on standardized forms that 
were maintained outside of the ward and then 
were assembled and analyzed after all patients in 
this cohort were discharged.
Metabolic Analysis
Serum samples were analyzed with a Piccolo 
Blood Chemistry Analyzer and Comprehensive 
Metabolic Reagent Discs (Abaxis), according to 
the manufacturer’s recommendations. We per-
formed metabolic measurements that included 
the levels of sodium, potassium, total carbon di-
oxide, chloride, glucose, calcium, blood urea ni-
trogen, creatinine, alkaline phosphatase, alanine 
aminotransferase (ALT), aspartate aminotrans-
ferase (AST), total bilirubin, albumin, and total 
protein.
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EBOV Diagnostics, Viral Load, and Genomics
We obtained samples using the collection and 
processing protocols at Kenema Government Hos-
pital under the emergency-response guidelines 
established by the Sierra Leone Ministry of Health 
and Sanitation. Diagnostic tests for the presence 
of EBOV were performed on site by means of 
quantitative reverse-transcriptase–polymerase-
chain-reaction (RT-PCR) assays with the use of 
the SuperScript III One-Step RT-PCR System with 
Platinum Taq DNA Polymerase (Life Technolo-
gies). EBOV RNA was quantified with the use of 
the Power SYBR Green RNA-to-CT 1-Step quanti-
tative RT-PCR assay (Life Technologies) at Har-
vard University, as described previously.5 Amplicon 
concentrations were converted to EBOV copies 
per milliliter for quantification. We sequenced a 
set of 99 EBOV isolates obtained from 78 patients 
and compared the results with all published 
EBOV sequences, as described previously.5 (All 
sequence data are available at the National Center 
for Biotechnology Information [NCBI BioGroup, 
PRJNA257197].)
Ethics and Biosafety Review
The institutional review board at Tulane Univer-
sity, the ethics committee at Harvard University, 
and the Sierra Leone Ethics and Scientific Review 
Committee approved this project. These commit-
tees waived the requirement to obtain informed 
consent during the West African Ebola outbreak. 
All clinical samples and data were collected for 
routine patient care and for public health inter-
ventions. The institutional biosafety committees 
at Tulane and Harvard and the Sierra Leone Ethics 
and Scientific Review Committee reviewed and 
approved biosafety protocols for this study.
Statistical Analysis
Multiple data sets representing EVD test results, 
patients’ medical charts, and metabolic findings 
were linked to restrict the study sample to pa-
tients who had observations with EVD test re-
sults. Results of descriptive analyses are reported 
as frequencies, proportions, and arithmetic means 
and medians. We used Fisher’s exact test to ana-
lyze hypotheses involving dichotomous variables. 
For cases in which a categorical variable was 
based on more than two categories, we used 
ordinary logistic regression to perform multiple 
comparisons. Hypotheses involving continuous 
variables were tested with the use of the Kruskal–
Wallis approach. We performed nonparametric 
multiple comparisons for continuous response 
variables by modeling their rank-ordered data 
values against a categorical variable classified ac-
cording to comparison groups. Hypothesis tests 
were two-tailed, with a P value of less than 0.05 
indicating statistical significance. Because of the 
observational nature of the data and the many 
tests that were performed, all P values should be 
interpreted cautiously. Statistical analyses were 
conducted with the use of SAS software, version 
9.3 (SAS Institute).
R esult s
Patients
A total of 213 patients who had an illness that 
met the definition for suspected Lassa hemor-
rhagic fever or EVD were tested between May 25 
and June 18, 2014, by means of conventional 
RT-PCR (Fig. S1 and Table S1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). Of these patients, 106 (50%) 
had positive results on testing for EBOV. The dis-
tribution of EVD according to age was bimodal, 
with peak incidences among children older than 
15 years of age and among adults between the 
ages of 26 and 40 years (Fig. S2 in the Supple-
mentary Appendix). Among confirmed cases, 59 
patients (60%) were female, including 1 pregnant 
woman who had a miscarriage immediately be-
fore her diagnosis. The majority of patients (92%) 
originated in Kailahun District, and most of them 
(82%) came from two chiefdoms in that district, 
Jawei and Kissi Teng (Tables S1 and S2 and Fig. 
S3 in the Supplementary Appendix).
Our previous sequencing studies identified 
three genetically distinct clusters of EBOV among 
patients with EVD in Sierra Leone (Fig. S3, S4, 
and S5 in the Supplementary Appendix). Groups 
of patients with identical viral genomes or groups 
in which genetic variation was shared among 
patients showed temporal, geographic, and intra-
personal relationships. These relationships al-
lowed us to observe incubation periods of 6 to 
12 days, which is similar to that observed in the 
outbreak overall.14 The mean (±SE) time from 
the onset of symptoms to presentation and hos-
pital admission was 5.7±0.5 days (Table S3 and 
Fig. S6 in the Supplementary Appendix), and the 
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mean time from the patient-reported onset of 
symptoms to death was 9.8±0.7 days (Table S3 
in the Supplementary Appendix). Patients who 
survived EVD were discharged after a mean du-
ration of illness of 21.3±2.6 days and a mean 
hospital stay of 15.3±3.1 days. Discharge oc-
curred when a patient was asymptomatic for at 
least 48 hours and blood samples were negative 
for EBOV on RT-PCR assay.
An overall case fatality rate of 74% was ob-
served among the 87 patients with a known out-
come. Survival outcomes could not be deter-
mined for 19 patients because they could not be 
contacted after providing an initial blood sam-
ple, they died before arrival at Kenema Govern-
ment Hospital, or they were lost to follow-up. 
Patients who were younger than 21 years of age 
had a significantly lower case fatality rate than 
did patients older than 45 years of age (57% vs. 
94%, P = 0.03 (Fig. 1A, and Table S2 in the Sup-
plementary Appendix). Patients between the ages 
of 21 and 45 years had an intermediate case fa-
tality rate of 74%. There was no significant dif-
ference in the case fatality rate between males 
and females (73% and 75%, respectively).
Viral Load
We determined the viral load of EBOV at the time 
of presentation in 65 patients with a known out-
come by means of quantitative RT-PCR. A posi-
tive correlation was noted between the viral load 
and the risk of death. Patients who presented 
with fewer than 100,000 EBOV copies per millili-
ter of serum had a case fatality rate of 33%, 
whereas those with a viral load of 10 million 
EBOV copies per milliliter or more had a signifi-
cantly higher case fatality rate of 94% (P = 0.003) 
(Fig. 1B, and Table S2 in the Supplementary Ap-
pendix). Viral loads were quantified for a limited 
number of patients at multiple times during their 
hospitalization, with results suggesting that an 
inability to clear the virus was a risk factor for 
death, even though some patients with prolonged 
viremia survived (Fig. S7 in the Supplementary 
Appendix).
Symptoms, Vital Signs, Physical Findings,  
and Treatment
Data regarding signs and symptoms in patients 
at the time of presentation were available for 44 
of 106 patients (Table S4 in the Supplementary 
Appendix). Although biased by the case defini-
tion, common findings included fever (in 89% of 
the patients), headache (in 80%), weakness (in 
66%), dizziness (in 60%), diarrhea (in 51%), ab-
dominal pain (in 40%), sore throat (in 34%), 
vomiting (in 34%), and conjunctivitis (in 31%) 
(Fig. 2, and Table S5 in the Supplementary Ap-
pendix). The only symptoms that were signifi-
cantly associated with a fatal outcome were 
weakness (P = 0.003), dizziness (P = 0.01), and di-
arrhea (P = 0.04). Among patients with diarrhea, 
94% died, whereas only 65% of those without 
diarrhea on presentation died. Evidence of bleed-
ing was noted in only 1 patient. None of the oth-
er 43 patients were reported to have hemorrhagic 
signs during their hospital stays, but the possi-
bility cannot be definitively excluded because of 
the limited charting.
Vital signs were recorded at presentation and 
every 6 hours thereafter. A fever (temperature, 
>38.4°C [101.1°F]) was recorded at the time of 
initial presentation in 13% of the patients, where-
as a temperature of 38°C (100.4°F) or more was 
noted in 29%. Temperature was the only vital 
sign that correlated with survival (Fig. 3A, and 
Table S6 in the Supplementary Appendix). The 
mean temperature at the time of admission was 
significantly higher among patients who died 
than among those who survived (37.5°C [99.5°F] 
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Figure 1. Case Fatality Rates among Patients with Ebola Virus Disease (EVD) 
in Sierra Leone.
Shown are case fatality rates among patients with confirmed EVD, a known 
outcome, and available data, according to age and viral load.
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vs. 35.9°C [96.6°F], P = 0.001). A review of all vital 
signs that were recorded showed that 20 patients 
had at least one temperature reading of 38.3°C 
or more during their hospital course. All but 
5 patients met the criteria for relative bradycar-
dia, with a mean temperature of 38.9±0.5°C 
(102.0±32.9°F) and a mean heart rate of 87±17.8 
beats per minute (Fig. S8 in the Supplementary 
Appendix).15 There were no significant differ-
ences between case patients with fatal EVD and 
those with nonfatal EVD with respect to other 
vital signs (Fig. 3B through 3F).
All 44 patients were given intravenous fluids. 
Four of the patients (9%) received antimalarial 
and antibacterial drugs before referral for EBOV 
testing. During their hospitalization on the viral 
hemorrhagic fever ward, 55% of the patients 
received antimalarial drugs and 93% received 
antibacterial drugs (Table S7 in the Supplemen-
tary Appendix). The most commonly administered 
antibiotic was ceftriaxone (in 80% of patients). 
Patients also received ampicillin (16%), metroni-
dazole (14%), and ciprofloxacin (5%). Several 
patients received more than one antibacterial 
agent. A total of 27% of patients were also 
treated with paracetamol.
Metabolic Testing
At the time of presentation, abnormalities in sev-
eral metabolic measurements were accurate pre-
dictors of the EVD diagnosis. Significant eleva-
tions in blood urea nitrogen, creatinine, AST, 
ALT, and alkaline phosphatase were noted among 
patients with EVD, as compared with febrile pa-
tients who were EBOV-negative and healthy vol-
unteers (Table S8 and Fig. S9 in the Supplemen-
tary Appendix). EBOV-negative patients, many of 
whom had malaria or other febrile illnesses and 
were seriously ill, had lower levels of total carbon 
dioxide and higher AST and ALT levels than did 
healthy volunteers. High levels of creatinine, 
blood urea nitrogen, and AST were significantly 
associated with a fatal EVD outcome (Fig. 4, and 
Tables S9 and S10 in the Supplementary Appen-
dix). There was no significant difference between 
patients with fatal cases and those with nonfatal 
cases in other metabolic measures at presenta-
tion, including levels of total carbon dioxide, 
alkaline phosphatase, and ALT.
Analysis of metabolic measures in patients 
for whom more than one blood sample was ob-
tained showed that normal or decreasing levels 
of blood urea nitrogen, creatinine, alkaline phos-
phatase, ALT, and AST and normal or increasing 
levels of total carbon dioxide heralded recovery 
(Fig. S10 in the Supplementary Appendix). Most 
patients who died from EVD had acidosis on 
admission or acidosis that developed during hos-
pitalization. Among patients who died, levels of 
blood urea nitrogen and creatinine progressively 
increased over time, suggesting that dehydration 
and worsening renal function played a signifi-
cant role in their hospital course. Patients who 
died were more likely to have sustained eleva-
tions in AST, ALT, or alkaline phosphatase (espe-
cially AST) than were patients who survived. Total 
bilirubin was mildly elevated in only one patient 
who died, suggesting that hemolysis and hepatic 
failure are not major components of EVD.
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Figure 2. Signs and Symptoms in Patients with Fatal and Nonfatal EVD.
Shown are signs and symptoms at presentation among patients with con-
firmed EVD, which were assessed by a review of the charts of patients who 
had known outcomes. The only symptoms that were significantly associated 
with a fatal outcome were weakness, dizziness, and diarrhea. Any fever at 
presentation was not associated with a fatal outcome. However, a tempera-
ture above 38°C (100.4°F) had such an association.
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Development of a Scoring System
Scoring systems, such as the modified Acute 
Physiology and Chronic Health Evaluation 
(APACHE), have been used in resource-limited 
settings as prognostic indicators.16,17 Although 
such a system for the evaluation of EVD would 
require validation before it could be used, it may 
be possible to develop a system similar to 
APACHE to predict the risk of death with the use 
of clinical data that are available on presentation. 
Other measures that were found to differ signifi-
cantly between patients with fatal EVD and those 
with nonfatal EVD are shown in Table S11 in the 
Supplementary Appendix.
Discussion
At Kenema Government Hospital, the research 
infrastructure was already in place to allow for 
data collection at the beginning of the EVD out-
break in Sierra Leone. In this retrospective analy-
sis of the viral and clinical characteristics of the 
patients with EVD, several demographic and 
clinical characteristics were associated with a 
fatal outcome, including an age of more than 
45 years. The effect of age on EVD has been noted 
in past outbreaks and remains a feature of the 
disease that has emerged in West Africa.18 A low 
virus load at presentation was associated with a 
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Figure 3. Vital Signs in Patients with Fatal and Nonfatal EVD.
Shown are findings for six vital signs at presentation in patients with confirmed EVD who had known clinical out-
comes, according to a review of chart data. Blue shading indicates normal ranges for the measurements. The only 
vital sign at presentation that was significantly associated with a fatal outcome was increased body temperature 
(above 38°C [100.4°F]). The T bars indicate standard errors.
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nonfatal outcome. Nearly all the patients with 
EVD who presented to Kenema Government Hos-
pital had a recent history of fever. A documented 
fever (temperature, >38°C [100.4°F]), weakness, 
dizziness, and diarrhea on presentation were 
also associated with a fatal outcome. A number 
of dysfunctional hematologic and blood-system 
features have been described in experimental 
animals infected with EBOV.19,20 Only 1 of 106 
patients in our study cohort had overt bleeding at 
presentation. Although bleeding has been noted 
in previous outbreaks, our results show that this 
symptom is rare in the current outbreak.14 As in 
past EVD outbreaks,21,22 we observed clotting ab-
normalities, including vaginal bleeding in preg-
nant women, hematemesis, and oozing at intra-
venous catheter sites, which require further 
investigation (data not shown).
We found evidence of hepatocellular damage 
and impaired kidney function, as assessed on 
metabolic testing at presentation, in patients who 
died of EVD as well as in those who survived. 
However, increased deviation from normal val-
ues predicted a fatal outcome. As in previous 
studies, AST values were consistently higher 
than ALT values, which suggests that tissue 
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Figure 4. Comparison of Metabolic Measures in Patients with Fatal and Nonfatal EVD.
Laboratory measurements at presentation that were associated with a fatal outcome included elevated levels of blood 
urea nitrogen, creatinine, and aspartate aminotransferase (AST). Blue shading indicates normal ranges for the vari-
ous measures. Results for sodium, potassium, chloride, glucose, calcium, albumin, total protein, and total bilirubin 
are provided in Table S10 in the Supplementary Appendix. The T bars indicate standard errors. ALT denotes alanine 
aminotransferase. To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357. To convert 
the values for creatinine to micromoles per liter, multiply by 88.4.
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damage, including rhabdomyolysis, may play a 
role in EVD.23 Future studies should include 
measurement of creatine kinase levels. Patients 
who recovered from the illness had normaliza-
tion of levels of liver enzymes, creatinine, total 
carbon dioxide, blood urea nitrogen, and other 
markers, often over the span of a few days.
At Kenema Government Hospital, all the pa-
tients were treated by staff members who were 
experienced in the care of patients with viral 
hemorrhagic fever, and all the patients received 
intravenous fluids and other supportive care. Be-
cause local staff members had expertise in man-
aging viral hemorrhagic fever, they were willing 
to provide clinical care for highly infectious pa-
tients and undertake invasive procedures that 
provided the basis for this data set. As the EVD 
outbreak in West Africa continues to spread on 
an unprecedented scale, the challenge of provid-
ing the most effective patient care is compound-
ed. The handling of diarrhea and vomitus, which 
can contain infectious EBOV,24 poses a threat of 
infection to health care workers and cleaners, 
and precautions should be emphasized in pre-
ventive training. However, it is incumbent on 
health care professionals to ensure that EVD 
facilities are focused on treating and improving 
the survival of patients, rather than merely on 
providing a setting for quarantine. The clinical 
and laboratory findings that we describe here 
should provide some insight for the rational 
design of clinical strategies aimed at improving 
care in this and future EVD outbreaks.
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